搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
过去 7 天
时间不限
过去 1 小时
过去 24 小时
过去 30 天
按时间排序
按相关度排序
2 小时
Looking at 2025, Health: Breakthroughs of hope and promise
Weight-loss treatments are on the cusp of a revolution, and could benefit large numbers of Indians after the main patent ...
6 小时
The Zepbound Shortage Is Over — Here's What to Expect if You've Been Using a Compounding ...
Patients taking a compounded alternative to Eli Lilly's weight loss drug Zepbound will need to transition to the name-brand ...
KSL
8 小时
Lilly's weight-loss treatment Zepbound becomes first FDA-approved drug for sleep apnea
WASHINGTON — The U.S. Food and Drug Administration on Friday approved Eli Lilly's weight-loss treatment ... as well as losing ...
10 小时
Musk Tests Mounjaro, Ozempic, Wegovy: Which Weight-Loss Drug Won Him Over?
Mounjaro and Ozempic are both GLP-1 receptors that can be used to help people with diabetes. The treatments are also ...
Mountain Democrat
10 小时
California Medicaid Spent $1.4B on GLP-1s for Obesity Over the Past 12 Months
Ozempic, Wegovy, and other GLP-1 receptor agonists have become a game-changer in obesity treatment, but their high ...
KSJB AM
11 小时
Which State Medicaid Programs Cover GLP-1s for Weight Loss & How Much Are They Spending?
The growing popularity of GLP-1 receptor agonists—including Ozempic and Wegovy from Novo Nordisk, and Mounjaro and Zepbound ...
Hastings Tribune
11 小时
Kansas Medicaid Spend on GLP-1s for Obesity up 97% Year-Over-Year
Ozempic, Wegovy, and other GLP-1 receptor agonists have become a game-changer in obesity treatment, but their high ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈